Jason J. Luke, MD, assistant professor of Medicine, The University of Chicago Medicine, discusses the controversy surrounding the combination of nivolumab (Opdivo) and ipilimumab (Yervoy) in treatment-naïve patients with advanced melanoma, which was explored in the CheckMate-067 trial, during the AACR Annual Meeting. The combination gained regulatory approval based on response rate and progression-free survival, with the assumption that those results would translate to overall survival (OS), Luke explains. Results of the CheckMate-067 study, reported at AACR, confirmed there was a 12% improvement in OS, however, there is still a question of whether the OS improvement justifies the extreme increase in toxicity with the addition of ipilimumab, relative to PD-1 monotherapy. While doctors continue to have differing opinions on the subject, Luke says his group is interested in exploring how to maximize benefit and minimize toxicity. One possible way to do this is with IDO inhibitor combinations, Luke says, for example, leading in with a PD-1 combination with high efficacy and low toxicity, and then using a CTLA-4 or ipilimumab-based regimen in the second-line setting if a patient progresses.
Views: 1190 OncLiveTV
Our panel of immunotherapy experts discusses the latest cancer immunotherapy advances featured at the world’s largest oncology conference—the 2018 annual meeting of the American Society of Clinical Oncology (ASCO)—with topics including combination immunotherapy, biomarker development, CAR T cell therapies, and new approaches to immune-based cancer treatment. Panelists include Charles G. Drake, M.D., Ph.D., of NewYork-Presbyterian/Columbia University Medical Center, and Catherine Diefenbach, M.D., and Jeffrey S. Weber, M.D., of the Perlmutter Cancer Center at NYU Langone Health. Jill O'Donnell-Tormey, Ph.D., of the Cancer Research Institute, moderates. We present this video as part of the Answer to Cancer patient and caregiver education program of the Cancer Research Institute, and feature it as part of our sixth annual global awareness campaign, Cancer Immunotherapy Month, in June. This panel was recorded on June 4, 2018, in Chicago, IL.
Views: 1159 Cancer Research Institute
Keytruda ( pembrolizumab ) is a new cancer drug to treat advanced melanoma, the deadliest form of skin cancer. An anti-body drug, administered intravenously, it uses the patient's immune system to attack cancer cells. Melanoma currently accounts for nearly 5% of all new cancers in the United States.This drug was developed by Merck.to help treat advanced melanoma that has spread or cannot be surgically removed.
Views: 10635 CancerIS
Roy Herbst, MD, PhD, and Everett Vokes, MD, describe their approach to treating non–small cell lung cancer that progresses on a PD-1 or PD-L1 inhibitor.
Views: 272 OncLiveTV
Beth Eaby-Sandy MSN, CRNP, OCN, of the Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA explains the different toxicities seen with immunotherapy compared to chemotherapy. Toxicities associated with immunotherapy are generally uncommon, but can be life threatening if they progress. It important for nurses to understand why these patients are having these toxicities, and how they differ from chemotherapy. Nurses must tell patients when to get in contact. Three of the most common severe immune-mediated toxicities from immunotherapies used in lung cancer are: pneumonitis, colitis, and rash/dermatitis. Pneumonitis and colitis are the two that can be life-threatening. Patients with pneumonitis may develop sudden in shortness of breath, chest tightness, or coughing. Such toxicities are reversible with high doses of steroids followed by about a months’ worth of a taper. Patients with colitis often confuse symptoms with diarrhea. The difference is that in diarrhea frequent and loose stools are seen. In colitis abdominal pain, cramping, with bloody or mucousy stools are seen. Colitis without treatment with high-dose steroids can rapidly become worse. It is important for HCPs to realize the greater concern of pneumonitis in lung cancer patients when compared to melanoma patients. The rash/dermatitis is not necessarily life-threatening. But it is important to evaluate with pictures, and possibly biopsy the skin lesion. This tends to be rare with lung cancer drugs, but more common and severe in melanoma with combinations of ipilimumab and nivolumab. Another wide range of common toxicities are endocrinopathies. Hypothyroidism causes TSH levels to go up meaning a need to supplement with levothyroxines (treatment of choice). Hyperthyroidism is less common and more difficult to treat. Hypophysitis, or pituitary or adrenal disorders, can also occur but are rare and treated accordingly with hormones or cortisol therapies. There are many other rare toxicities, for example ocular toxicities, neuromuscular toxicities. Hepatitis and nephritis are slightly more common but are ‘paper toxicities’, which patients don’t feel and can be managed. Recorded at the 2016 World Conference of Lung Cancer (WCLC) of the International Association for the Study of Lung Cancer (IASLC) in Vienna, Austria.
Views: 546 VJOncology
Jeffrey S. Weber, MD, PhD, deputy director and co-director of the Melanoma Program at the Laura and Isaac Perlmutter Cancer Center at NYU Langone Medical Center, discusses the toxicity profile seen with nivolumab (Opdivo) versus ipilimumab (Yervoy) for patients with melanoma.
Views: 157 OncLiveTV
Approximately 75% of patients with advanced renal-cell carcinoma have an intermediate or poor prognosis, with a low rate of response to standard treatment with sunitinib and a high rate of toxic effects. Full trial results: http://nej.md/2GaYWq9 Watch more Quick Take videos: http://nej.md/quick-take
Views: 1457 NEJMvideo
Despite his initial prognosis of six to eight months to live, Ronald Eckert, MD, is thriving after undergoing a new immunotherapy treatment for stage 4 melanoma. Four years after the treatment, he feels he is cured and shares his story. Medical experts discuss the groundbreaking immunotherapy research and treatments being discovered each day in the area of cancers—treatments that will change the way we look at cancer. Visit http://www.SecondOpinion-TV.org Funded by Blue Cross Blue Shield Association: http://www.bcbs.com/
Views: 1119 Second Opinion
Zelig Eshhar explains his breakthrough cancer treatment. The CAR T therapy has revolutionized cancer research, and ultimately the search for a cure. Charles Mizrahi, Founder of Park Avenue Investment Club, traveled to Israel to meet with the award winning professor, and to learn more about his breakthrough research.
Views: 296 Park Avenue Digest
Robert J. Motzer, MD, medical oncologist at Memorial Sloan Kettering Cancer Center, 2016 Giant of Cancer Care in Genitourinary Cancer, discusses the data seen thus far with nivolumab plus ipilimumab in the treatment of patients with renal cell carcinoma.
Views: 305 OncLiveTV
Animation examines recent advancements in immunotherapy that harness the power and specificity of the immune system to fight cancer. This scene focuses on how antibody blockade of CTLA4 binding to B7 prevents the suppression of cytotoxic T cell function that would normally occur.
Views: 4294 Interactive Learning
Matthew D. Hellmann, MD, Memorial Sloan Kettering Cancer Center, discusses the CheckMate-032 study investigating nivolumab (Opdivo) with or without ipilimumab (Yervoy) for patients with small-cell lung cancer (SCLC).
Views: 118 OncLiveTV
For the first time, a treatment that boosts the immune system greatly improved survival in people newly diagnosed with the most common form of lung cancer.It's the biggest win so far for immunotherapy, which has had much of its success until now in less common cancers.In the study, Merck's Keytruda, given with standard chemotherapy, cut in half the risk of dying or having the cancer worsen, compared to chemo alone after nearly one year.The results are expected to quickly set a new standard of care for about 70,000 patients each year in the United States whose lung cancer has already spread by the time it's found.Another study found that an immunotherapy combo - the Bristol-Myers Squibb drugs Opdivo and Yervoy - worked better than chemo for delaying the time until cancer worsened in advanced lung cancer patients whose tumors have many gene flaws, as nearly half do.But the benefit lasted less than two months on average and it's too soon to know if the combo improves overall survival, as Keytruda did.All of these immune therapy treatments worked for only about half of patients, but that's far better than chemo has done in the past.'We're not nearly where we need to be yet,' said Dr. Roy Herbst, a Yale Cancer Center lung expert who had no role in the studies.Results were discussed Monday at an American Association for Cancer Research conference in Chicago and published by the New England Journal of Medicine. The studies were sponsored by the drugmakers, and many study leaders and Herbst consult for the companies.Keytruda, Yervoy and Opdivo are called checkpoint inhibitors. They remove a cloak that some cancer cells have that hides them from the immune system. The drugs are given through IVs and cost about $12,500 a month.Keytruda was approved last year as an initial treatment with chemo for the most common form of advanced lung cancer, but doctors have been leery to use it because that was based on a small study that did not show whether it prolongs life.The new study, led by Dr. Leena Gandhi of NYU's Perlmutter Cancer Center, gives that proof. In it, 616 patients were given chemo and some also received Keytruda. Those not given Keytruda were allowed to switch to it if their cancer worsened.After one year, 69 percent of people originally assigned to Keytruda were alive versus 49 percent of the others - a result that experts called remarkable considering that the second group's survival was improved because half of them wound up switching.How much it ultimately will extend life isn't known - more than half in the Keytruda group are still alive; median survival was just over 11 months for the others.The Keytruda combo also delayed the time until cancer worsened - an average of nine months versus five months for the chemo-only group.That's a big difference for such an advanced cancer, said Dr. Alice Shaw, a Massachusetts General Hospital lung cancer expert and one of the conference leaders. 'This is really a pivotal study ... a new standard of care,' sa AutoNews- Source: http://www.dailymail.co.uk/health/article-5621411/Immune-therapy-scores-big-win-against-lung-cancer-study.html?ITO=1490&ns_mchannel=rss&ns_campaign=1490
Views: 12 US Sciencetech
Dirk Schadendorf, MD, PhD, from the University Hospital Essen, Essen, Germany, discusses developments in melanoma treatment at the European Cancer Congress of the European Cancer Organisation (ECCO) 2017 in Amsterdam, Netherlands. He describes how epidemiological data suggest that while the incidence of melanoma is increasing by 5% each year, a 25% decrease in melanoma-related mortality is expected by 2050. Prof. Schadendorf suggests factors which will be important in achieving this, particularly prevention and early detection, which is linked to access to the healthcare system including dermatologists to allow early diagnosis. Currently, interferon alpha is used as adjuvant therapy, however, several new drugs have shown promising results, both immune checkpoint inhibitors such as ipilimumab and next-generation PD-1 antibodies pembrolizumab and nivolumab, as well as targeted therapies for patients with BRAF mutations. As these therapies are novel, the full extent of their effects will only become apparent in the next years.
Views: 91 VJOncology
Prof Sharma talks to ecancertv at ECC 2015 about the targeted drug nivolumab, and how it significantly prolongs survival in patients with advanced kidney cancer, whose disease has progressed after their first treatment. In the interview she highlights the findings of the CheckMate 025 trial, an open-label, phase III trial that compared the PD-1 checkpoint inhibitor nivolumab against everolimus in previously treated patients with metastatic renal cell carcinoma (mRCC). Based on the results of this trial, the US Food and Drug Administration granted nivolumab a breakthrough therapy designation for mRCC. Prof Sharma also comments on the potential for using nivolumab in combination with other targeted anticancer agents, such as ipilimumab.
Views: 612 ecancer
First-of-its-kind study indicates pretreatment improves outcomes over standard-of-care surgery A pair of targeted therapies given before and after surgery for melanoma produced at least a six-fold increase in time to progression compared to standard-of-care surgery for patients with stage 3 disease, researchers at The University of Texas MD Anderson Cancer Center report in Lancet Oncology. Early results of the study comparing surgery to pre- and post-surgical treatment with the BRAF inhibitor dabrafenib and the MEK inhibitor trametinib were so strikingly positive that MD Anderson’s data safety monitoring board ordered the randomized, prospective phase II trial halted and changed to a single-arm using the combination. “These results are encouraging for patients with surgically resectable stage 3 melanoma, who face a high rate of relapse and progression to metastatic disease,” said lead author Rodabe Amaria, M.D., assistant professor of Melanoma Medical Oncology. “Our proof-of-concept study strongly supports further assessment of neoadjuvant (presurgical) therapy for this high-risk population, which has a five-year survival rate of less than 50 percent.” The targeted combination is approved by the U.S. Food and Drug Administration for stage 4 metastatic melanoma that features a BRAFV600 mutation. Amaria, senior author Jennifer Wargo, M.D., associate professor of Surgical Oncology and Genomic Medicine, and colleagues hypothesized that the combination could help patients with stage 3 BRAF-mutant disease. Trial launched through Moon Shots Program In October 2014, the investigator-initiated clinical trial was launched through the Melanoma Moon Shot™, co-led by Wargo and part of MD Anderson’s Moon Shots Program™ to accelerate improvement of cancer treatment and prevention. It was the first prospective, randomized neoadjuvant clinical trial for stage 3 melanoma. The trial was designed to enroll 84 patients randomized to either up-front surgery or to eight weeks of the targeted combination followed by surgery and another 44 weeks of combination treatment. An interim data analysis occurred after 21 patients were treated. At a median follow-up time of 18.6 months: · All seven treated with standard of care surgery had their disease progress, with median time to progression at 2.9 months. · Of 14 randomized to the neoadjuvant combination, four progressed, with median time to progression of 19.7 months. · Of the seven patients who achieved a pathological complete response after presurgical therapy, none experienced distant disease relapse. · Median overall survival had not been reached in either arm. Most melanoma is detected at early stages and treated successfully with surgery, but about 15 percent of patients progress to stage 3, when the disease has spread to lymph nodes. Patients with stage 4 disease but with fewer than four resectable metastases also are enrolled in the trial. Importance of pathological complete response Reaching pathological complete response (pCR) – no evidence of cancer found by pathology at surgery – appears to be a powerful indicator of treatment success, Wargo said. Twelve patients in the neoadjuvant group proceeded to surgery, with seven achieving pCR. Only one relapsed, with a small tumor in the same area as the original tumor. Three patients who reached a partial pathological response relapsed, with all developing brain metastases, a common risk in BRAF-positive disease. “As we accumulate more data, we can further explore the importance of pathological complete response,” Wargo said. “If we can prove that pathologic complete response is important in achieving superior outcomes, then the next step is to ask ‘what can you do to get to pCR?’”
Views: 418 MD Anderson Cancer Center
The Event Is Coming Soon - Deadly Chemo-Drug Costs 4,000x More Than Gold Author's Name: by Edward Morgan Read More/Article Source Link/Credit(FAIR USE):https://prepareforchange.net/2018/05/09/deadly-chemo-drug-costs-4000x-more-than-gold/ The Event Is Coming Soon distributes this material for the purpose of news reporting, educational research, comment and criticism, constituting Fair Use under 17 U.S.C § 107. Please contact the Editor at TheEventIsComingSoon@gmail.com with any copyright issue. One of the oldest marketing tricks in the book is to dramatically overprice something in order to increase its perceived value. Ironically, the less intrinsic value the commodity holds, the more effective such a tactic can be. This could explain what’s going on with one of the highest priced and most useless chemotherapy drugs on the market today. The chemotherapy agent is known as ipilimumab (trade name YERVOY®), and costs about $120,000 for a full course of treatment. While the manufacturer advertises YERVOY® as providing tangible hope to those with non-resectable or metastatic melanoma, it also boldly warns on its website that the effects of this drug can be quite deadly: What are the serious side effects of YERVOY? YERVOY can cause serious side effects in many parts of the body which can lead to death. The serious side effects of YERVOY may include intestinal problems (colitis) that can cause tears or holes (perforation) in the intestines; liver problems (hepatitis) that can lead to liver failure; skin problems that can lead to severe skin reaction; nerve problems that can lead to paralysis; hormone gland problems (especially the pituitary, adrenal, and thyroid glands); and eye problems.” https://www.dailymotion.com/theeventiscomingsoon To Your Health Body and Spirit https://www.youtube.com/channel/UCDs86lPm4dF5kfMOA94TSKQ Onstellar Link: https://onstellar.com?referral=s1t ----------------------------------------------------------- Please visit our Playlist for additional intel: The Event Intel https://www.youtube.com/playlist?list=PLZX49q1VM8O0p0XzU10aCLsSS92iTVQeg Disclosure https://www.youtube.com/playlist?list=PLZX49q1VM8O0C40VKZcQt-GRdpRaUy4lh Politics https://www.youtube.com/playlist?list=PLZX49q1VM8O0wTVaYupBh1Rq17yto_52t Energy Update https://www.youtube.com/playlist?list=PLZX49q1VM8O00lKekMXttP5HJvoGEQgPa&disable_polymer=true Newest Videos https://www.youtube.com/playlist?list=PLZX49q1VM8O0c5ifCAZSE3J0pRR9BcgUI The Event Is Coming Soon https://www.youtube.com/channel/UCNdcqCdkJ-EFv0IEU79MDUA SUPPORT US USING OUR LINKS! https://youtu.be/G8bQkAOUILE ----------------------------------------------------- http://twitter.com/eventcomingsoon
Views: 270 The Event Is coming soon
Dan Chen MD, PhD from Stanford Medical Oncology and Genentech describes brilliantly how our immune system detects cancer cells and how tumors get past our immune system through PD-L1, PD-1, and B7.1 interactions. A must see!!! Brilliant way to understand the effects of checkpoint inhibitors and cancer immunotherapy.
Views: 127419 ImmunoOncology
Dr Weber presents in a press conferene at the ESMO 2017 Congress in Madrid the data from a large, randomised, phase III trial in which patients with stage IIIb/c/IV melanoma, identified as high risk individuals, were treated with either nivolumab or ipilimumab. Dr Weber goes on to discuss the clinical and statistical benefit of nivolumab compared to ipilimumab with a 35% reduction in the risk of relapse and a 13% difference in 18 month relapse free survival rates, in favour of nivolumab. More from ESMO 2017 : http://ecancer.org/conference/722-esmo-2017.php Ecancer website: http://ecancer.org/video/index.php Twitter: @ecancer Facebook: https://www.facebook.com/ecancer
Views: 167 ecancer
English/Nat Scientists in the U-S are hopeful they have discovered a treatment which - if proven successful in human trials - could kill cancer cells without harming healthy cells around them. A scientific team at the University of California in Los Angeles has found promising results in lab tests with a boron-based neutron therapy that could lead to a less harsh alternative to traditional chemotherapy. But while the U-C-L-A chemists believe their experimental research could revolutionise cancer treatment, oncologists are skeptical of the findings until human tests are conducted. These cancer patients are being treated with chemotherapy. The chemicals involved are strong enough to destroy cancer cells, but more often than not also kill many healthy ones with them. This leaves many cancer patients sick from the treatment and struggling with side effects on top of their cancer itself. But now, a new therapy is being tried out that could treat cancer with none of the damaging effects of chemotherapy. Chemist M. Frederick Hawthorne and his scientific team at the University of California at Los Angeles, or U-C-L-A, have discovered a boron-based neutron therapy that could eventually lead to a less harsh form of cancer treatment. Scientists in the 1930's came up with the idea of using boron-based compounds against cancer. But Hawthorne and his team has found a new group of chemicals that proved effective in the lab at delivering the boron directly into the nucleus of the cancer cell where the deoxyribonucleic acid, or DNA, resides. Since their findings were discovered in a laboratory setting, several years of clinical trials on humans still need to be conducted and prove successful. If the theory is a success in human tests, once the boron is delivered, a cancer patient will be exposed to a beam of neutrons that will selectively destroy the cells bound with the boron, leaving the healthy cells in tact. Hawthorne said he believes the process holds the promise not only of improving quality of life for cancer patients, but could lead to them seeing a remission or even a cure for their disease in the future. Professor Hawthorne explained how the technique singles out the cancerous cells. SOUNDBITE: (English) "(You) Introduce boron compounds which again seek out and selectively bind to brain tumour cells and enter those cells and then the brain, the whole head in fact, is irradiated with neutrons which are innocuous to normal tissue except those cells that have boron in them in which case we would blow up those cells and that would give you a way of very selectively destroying the bad guys surrounded by a population of normal, very high quality cells, brain cells." SUPERCAPTION: M. Frederick Hawthorne, UCLA Chemist Back in the lab, Hawthorne's scientists continue to fine-tune their potential boron compounds. The material can be highly combustible and lab technicians take protective measures to avoid injury. Hawthorne is hopeful the new finding might help facilitate the development of cures in the future for fatal types of cancers, like lung cancer. SOUNDBITE: (English) "We hope it will be actually a curative measure for normally fatal lung cancer." SUPERCAPTION: M. Frederick Hawthorne, UCLA Chemist As chief oncologist at University of Southern California (U-S-C) Cancer Center in Los Angeles, Dr. Derek Raghavan treats cancer patients daily with traditional chemotherapy. He finds Hawthorne's lab research interesting but warns boron-neutron therapy can still be dangerous and will require extensive human trials to prove it works. Raghavan has raised doubts over the boron therapy's ability to leave all healthy cells around the cancerous cell intact and unharmed. You can license this story through AP Archive: http://www.aparchive.com/metadata/youtube/940906d0115a6fb4af864530fde200c9 Find out more about AP Archive: http://www.aparchive.com/HowWeWork
Views: 73 AP Archive
Antoni Ribas, M.D. of the UCLA Jonsson Comprehensive Cancer Center is involved in trials testing new cancer drugs targeting the cell surface molecule called PD-L1, and the immune cell receptors PD1. Early data from these trails involving non-small cell lung cancer, renal cancer and melanoma have demonstrated impressive results that can lead to new treatments for the disease. In the video interview, Dr. Ribas explains the trial test data published so far, and previews new data to be seen at the upcoming American Society of Clinical Oncology (ASCO) meeting.
Views: 4662 UCLAJCCC
Prof Andtbacka speaks with ecancer at ASCO 2017 about results from a phase II multicenter trial combining intralesionally injected HF10, an oncolytic Herpes virus, with anti-CTLA4 targeted therapy to treat metastatic or unresectable melanoma He describes the encouraging response rates from the small trial group, with 41% overall response at 24 weeks, significantly more than trials using ipilimumab alone, with many patients experiencing a durable response. Prof Andtbacka notes pending analysis of patients responses to assess if age and immune senescence may influence these outcomes, and highlights further trials testing HF10 alongside other immune agents, including a similar trial ongoing in Japan. Intralesional oncolytic therapies were also discussed by Prof Sanjiv Agarwala at EADO 2017 .
Views: 59 ecancer
On www.xtalks.com - A Phase I clinical trial testing whether CAR-T cell immunotherapy could be a viable treatment for a type of brain cancer known as glioblastoma, has found that the therapy was both safe and effective. To read more: http://www.xtalks.com/CAR-T-Cell-Immunotherapy-For-Brain-Cancers-316.ashx For more news stories, visit: http://xtalks.com/News.ashx Receive weekly news updates right in your inbox: http://www.xtalks.com/subscribe.ashx Listen live and interact with featured speakers on our upcoming Life Science webinars: http://xtalks.com/upcoming.ashx
Views: 576 Xtalks Webinars
Jeffrey Weber, MD, PhD of the NYU Langone Medical Center, New York, NY, discusses his introductory plenary lecture on the revolution and evolution of immunotherapy in melanoma given at the 2016 World Congress of Cancers of the Skin (WCCS) and the Congress of the European Association of Dermato-Oncology (EADO) in Vienna, Austria. Prof. Weber highlights that first, he discussed how immunotherapy for melanoma has changed and developed over the years. He believes that it is clear that the revolution is the fact that we can now see what is described as the tail on the curve of survival. For the first time, we have patients who have long-term survival in melanoma, with the use of PD-1 blockade (ipilimumab with nivolumab), where some of the patients may be cured. This brings up the discussion of curing melanoma, a topic which has only just recently come about. Just 10-15 years ago, the median survival for melanoma patients was under a year, and the one year survival was around 35%. He highlights that matters have changed dramatically, with the new drug approvals within the US and the EU. Since 2011, we have had a 70%+ one year survival rates, and median survival has now tripled from what they were 10 years ago. What has evolved is that we now understand the immune-related adverse events, and we can now see the unusual kinetics of responses Additionally, he highlights that what will be a bit of a revolution, is the understanding that some patients do not respond to certain novel drugs because the tumor microenvironment is non-inflamed (also called a cold tumor microenvironment). Alongside this, he emphasizes that a better understanding of how we can convert a cold microenvironment to a warm microenvironment will be the next revolution, which would enable for the increase yet again the tail on the curve of survival and the potential for curing patients with melanoma.
Views: 72 VJOncology
Cancer kills approximately 8 million people annually and is difficult to treat, let alone cure. Immune checkpoint inhibitors have allowed physicians to make significantly more progress against advanced cancer than they’ve achieved in decades. Combined with traditional chemotherapy and radiation treatment, the novel drugs boost the immune system and offer significant, long-term cancer remissions for patients with metastatic melanoma, and there is increasing evidence that they can work on other types of malignancies. For more information about Medical Innovation Summit, visit http://summit.clevelandclinic.org/
Views: 10670 Cleveland Clinic
In this video, the leading Pathologists from Quest Diagnostics describe the new frontiers of immune-oncology treatment and explain the importance of Immunotherapy in treatment of Cancer. More detailed information on PD-L1 and PD-1 testing and test results that could change lives when eligible patients are identified and treatment decisions are made using immune-oncology therapy.
Views: 172 Quest Diagnostics
Michael A. Postow, MD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses the current treatment landscape in melanoma. With a wealth of agents in melanoma, researchers are now trying to decide which agents work best by themselves, in sequence, or in different combinations with one another, says Postow. Researchers are also currently exploring the use of targeted agents, such as trametinib (Mekinist) and cobimetinib (Cotellic), which are both MEK inhibitors. However, some attempts to combine targeted agents with immunotherapies are not always successful. For example, vemurafenib (Zelboraf) was not able to be combined with ipilimumab (Yervoy). Postow stresses the importance of carefully testing these combination therapies in the context of clinical trials.
Views: 158 OncLiveTV
Has your doctor mentioned the Oncotype DX test for colon cancer? This new diagnostic tool is helping doctors better quantify the risk of a cancer recurring. Doctors will modify your treatment according to your Oncotype DX score to give you the best treatment possible. Dr. Kelly Shimabukuro discusses how doctors use this new test in this short video. Learn why doctors are using the Oncotype DX tests more and more. VIEW THE ARTICLE: What is the Oncotype DX Test? - http://www.coloncanceranswers.com/?p=13110 LAST WEEK'S VIDEO - Is There a Grief Process After a Cancer Diagnosis? - http://www.youtube.com/watch?v=6WYgDC6rxiY SUBSCRIBE FOR MORE EXPERT INFORMATION AND BREAKING COLON CANCER NEWS http://www.youtube.com/subscription_c... VISIT COLONCANCERANSWERS.com FOR TONS OF INFORMATIVE VIDEOS http://www.coloncanceranswers.com/ SUGGEST THE NEXT TOPIC FOR OUR COLON CANCER EXPERTS! http://www.coloncanceranswers.com/ CONNECT WITH US! Google+ : http://bit.ly/169ii4g Facebook : https://www.facebook.com/ColonCancerA... Twitter : https://twitter.com/ColonCancerQA
Views: 119 Colon Cancer Answers
This video is from a Facebook Live discussion of advanced melanoma. Dr. Stephanie Goff of the National Cancer Institute and Dr. Jason Luke of the University of Chicago participated in the event, which was moderated by Jamie Troil-Goldfarb, a survivor of stage IV melanoma. https://www.cancer.gov/news-events/events/social-media
Views: 551 National Cancer Institute
Michael Brown, MBBS, FRACP, FRCPA from the Royal Adelaide Hospital, Adelaide, Australia discusses the history of cancer immunotherapy. Historically speaking, Dr Brown mentions there being a theory that the immune system may have some involvement in controlling cancer. Attempts have been made to stimulate the immune system against cancer, mainly to activate the innate immune system, using agents like interferon alpha or BCG. However, cancer has mechanisms to switch off the immune system. Interventions using anti-CTLA-4 antibodies, like ipilimumab, recognised that new specificities for cancer-related antigens were being generated by the use of ipilimumab to block the switch off mechanism that cancer can use. In addition, anti-PD-1 antibodies can interrupt tumor’s ability to switch off T-cell activity, which means that T-cells can recognise tumor antigens and potentially fight it. Recorded at the Multinational Association of Supportive Care in Cancer (MASCC) and International Society of Ocular Oncology (ISOO) 2016 Annual Meeting on Supportive Care in Cancer held in Adelaide, Australia.
Views: 85 VJOncology
PD-L1,a 40kDa type 1 transmembrane protein, is a PD-1 ligand that can deliver inhibitory signals to PD-1+ T-cells to suppress immune responses. PD-L1 is widely expressed in cancer, where it contributes to immune evasion and facilitates tumor growth. Immunotherapy for the treatment of cancer is rapidly evolving from therapies that globally and non-specifically simulate the immune system to more targeted activation of individual components of the immune system. More specifically, therapies that inhibit the interaction between PD-L1, present on the surface of tumor or antigen-presenting cells, and PD-1, present on the surface of activated lymphocytes, are generating much excitement and enthusiasm, even in malignancies that are not traditionally considered to be immunogenic.
Views: 13761 Proteinlounge
Dr. Jack West summarizes the rationale for testing immune checkpoint inhibitors as a first line treatment for patients with advanced NSCLC and highlights details of two trials testing this question. http://cancergrace.org/lung/2015/11/19/lcam_2015_west_first_line_immune_checkpoint_inhibitor_trials/
Georgina Long, BSc, PhD, MBBS, FRACP, medical oncologist, translational researcher, Melanoma Institute Australia, The University of Sydney, discusses the treatment of melanoma with emerging targeted therapies. For more resources and information regarding anticancer targeted therapies: http://targetedonc.com/
Views: 1036 Targeted Oncology
Jason J. Luke, MD, FACP, assistant professor of medicine, The University of Chicago, discusses the efficacy of PD-1/PD-L1 inhibitors in melanoma. The combination of these inhibitors, nivolumab and ipilimumab, was used to treat patients with previously untreated, unresectable or metastatic melanoma, in the Checkmate 069 study. Luke says PD-L1 is very complex and difficult when developing immunohistochemical assays. Since several pharmaceutical companies conduct different assays that test various things, a particular patient may be positive in one case, but not in another. For this reason, patients become very confused. Luke also mentions that there is no validated method across the board, so it is difficult to determine the next steps going forward.
Views: 161 Targeted Oncology
Prof Antoni Ribas, (UCLA Jonsson Comprehensive Cancer Center, Los Angeles, USA) talks to ecancertv at AACR 2015 about the findings of a phase III trial, which showed pembrolizumab to be preferable to ipilimumab in advanced melanoma.
Views: 772 ecancer
http://www.dailyrx.com/ipilimumab-plus-sargramostim-may-improve-survival-patients-advanced-melanoma-more-ipilimumab-alone?autoplay=928188608 A new study compared the safety and effectiveness of ipilimumab (brand name Yervoy) and ipilimumab plus sargramostim (brand name Leukine) for treatment of advanced melanoma. The researchers found that the combination medication improved patients' survival rates more than ipilimumab alone
Views: 495 dailyRx
Nicholas G. Cost, MD, assistant professor, Surgery-Urology, Department of Pediatric Urology/ Urologic Oncology, University of Colorado Denver, discusses a clinical trial exploring pembrolizumab (Keytruda) plus axitinib (Inlyta) in patients with renal cell carcinoma (RCC).
Views: 153 OncLiveTV
Mologen is a German biotech company developing cancer immunotherapies. Their lead product is Lefitolimod (MGN1703) which is being tested in a phase III trial for metastatic colorectal cancer (mCRC) and a phase II trial in small cell lung cancer (SCLC). Lefitolimod is also in a phase I trial for HIV and a combination trial with Yervoy, an immune checkpoint inhibitor. In this webcast, CEO Dr Mariola Söhngen explains how Lefitolimod is differentiated from its rivals and how its late stage trials are approaching major inflection points. She describes how their phase III trial for mCRC will have fully enrolled patients by year end and how the phase II trial in SCLC will see preliminary data analysis by end 16/start 17. She discusses how they have one of the few late stage immunotherapy assets in the world and how talks with licensing partners are ongoing. While a cash raise is needed this year preferably by licensing, a capital market fundraise is also an option. The early stage Lefitolimod trial in HIV and the combination trial with Yervoy are also summarised."
Views: 312 Edison
Oncologists throughout the country, as well as the Cancer Society of New Zealand, have been asking for immunotherapy treatments for melanoma from Pharmac since last year. Sarah Fitt, Pharmac's Director of Operations, joins Checkpoint.
Views: 1972 RNZ
Presented at: Microbiology & Immunology 2017: https://www.labroots.com/virtual-event/microbiology-2017 Presented by: Condie Carmack, PhD - Vice President of Precision Oncology, Vela Dx Speaker Biography: Condie Carmack, Ph.D. received his Ph.D. from the University of Utah in Experimental Pathology and did postdocs in Philadelphia, PA and San Diego, CA. in mouse genetics and molecular biology. He is the author or or co-author of 23 peer-reviewed journal. He wrote the first paper on quantitative PCR and the second paper on multiplex PCR. He served on the Science Advisory Board of Life Technologies Inc. as an expert in clinical PCR. He was co-author on the first paper creating human monoclonal antibodies from immunodeficient mice. Mice serve as the foundation for creation of the current immune checkpoint blockade antibodies such as ipilimumab and nivolumab. He also served as General Manager of the Cancer Genetics Lab at Baylor College of Medicine before joining Vela Diagnostics. Webinar: How Biomarker Testing Shapes Immunotherapy Abstract: The immune system is complex and dynamic, focused on defending the body from a host of pathogens ranging from viruses to cancer. A number of different mechanisms have evolved that help the body fight to control cancers and other disease. Unfortunately, sometimes these defenses break down and become compromised, enabling cancers to survive and grow within the host. Recent breakthroughs have shown that Immunotherapeutic approaches may be successful in helping the host's immune system battle cancer, providing the body with ways to protect itself from cancer. Key to making this work is an understanding of both who will benefit from the therapy and at what stage in disease progression the therapy will be effective. In our discussion we will look at how biomarker development can aide in addressing these challenges. We will cover: • Overview of Immunotherapies & their mechanisms of action • Biomarkers associated with Immunotherapies • Biomarker clinical testing • Immunotherapy adverse reactions & success stories Sponsored By: Vela Diagnostics Earn PACE/CME Credits: 1. Make sure you’re a registered member of LabRoots: https://www.labroots.com/virtual-event/microbiology-2017 2. Watch the webinar on YouTube above or on the LabRoots Website: https://www.labroots.com/virtual-event/microbiology-2017 3. Click Here to get your PACE: Credits expire on September 14, 2019 http://www.labroots.com/credit/pace-credits/2463/third-party LabRoots on Social: Facebook: https://www.facebook.com/LabRootsInc Twitter: https://twitter.com/LabRoots LinkedIn: https://www.linkedin.com/company/labroots Instagram: https://www.instagram.com/labrootsinc Pinterest: https://www.pinterest.com/labroots/ SnapChat: labroots_inc
Views: 114 LabRoots
Dr. Antoni Ribas discusses a new clinical trial at UCLA that uses interfering messenger RNA to help stop cancer cells from duplicating.
Views: 315 UCLAJCCC
Dr. Patrick Wen of Dana-Farber Cancer Institute discusses the National Brain Tumor Society's Clinical Trial Endpoints Initiative. See more here: http://tinyurl.com/l2owsmj
Views: 800 National Brain Tumor Society
Jeffrey S. Weber, MD, PhD, Laura and Isaac Perlmutter Professor of Oncology, deputy director, co-director of the Melanoma Research Program, NYU Langone’s Perlmutter Cancer Center, discusses the clinical potential and monetary hindrances of triplet and four-drug regimens for patients with melanoma.
Views: 116 OncLiveTV
Dr James Larkin, Consultant Medical Oncologist and advisor to Melanoma UK discusses the decision by NICE to approve pembrolizumab for advanced skin cancer patients.
Views: 250 Melanoma UK